APA (7th ed.) Citation

AD, S., AK, C., A, B., ME, M., D, L., A, F., . . . CA, H. (2013). Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. Clinical breast cancer, 13(4), 239. https://doi.org/10.1016/j.clbc.2013.02.008

Chicago Style (17th ed.) Citation

AD, Seidman, et al. "Randomized Phase II Trial of Weekly Vs. Every 2 Weeks Vs. Every 3 Weeks Nanoparticle Albumin-bound Paclitaxel with Bevacizumab as First-line Chemotherapy for Metastatic Breast Cancer." Clinical Breast Cancer 13, no. 4 (2013): 239. https://doi.org/10.1016/j.clbc.2013.02.008.

MLA (9th ed.) Citation

AD, Seidman, et al. "Randomized Phase II Trial of Weekly Vs. Every 2 Weeks Vs. Every 3 Weeks Nanoparticle Albumin-bound Paclitaxel with Bevacizumab as First-line Chemotherapy for Metastatic Breast Cancer." Clinical Breast Cancer, vol. 13, no. 4, 2013, p. 239, https://doi.org/10.1016/j.clbc.2013.02.008.